NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial.

Trial Profile

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Umirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms NEXT
  • Most Recent Events

    • 09 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Mar 2014 Results for vascular healing presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 28 Sep 2012 New source identified and integrated (University Hospital Medical Information Network, UMIN000004661)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top